The boss of cancer diagnostics group () reckons the awarding of a CE mark for its Nu.Q Colorectal Cancer Screening Triage test could be transformational for the firm.
Chief executive Reynolds tells Proactive: “This is a very big deal for us. It really shifts the company from an R&D company to a product company.”
“It’s an extremely rewarding time for us and something we’re very happy about”
Reynolds also gives investors a run-through of how the test works and how it will work alongside current cancer screening methods.
On top of that, the boss discusses the progress being made as a whole, including an update on the development facility in Belgium purchased last October.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE